Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
Want to see LXRX full AI Analyst Report?
LXRX Stock Chart & Stats
$1.87
-$0.12(-12.49%)
At close: 4:00 PM EST
$1.87
-$0.12(-12.49%)
Day’s Range― - ―
52-Week Range$0.72 - $2.53
Previous CloseN/A
Volume2.02M
Average Volume (3M)2.94M
Market Cap
$892.83M
Enterprise Value$925.78M
Total Cash (Recent Filing)$170.66M
Total Debt (Recent Filing)$57.71M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Jul 30, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding444,196,380
10 Day Avg. Volume2,131,254
30 Day Avg. Volume2,943,081
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue13.29
Enterprise Value/Gross Profit13.42
Enterprise Value/Ebitda-53.08
Forecast
1Y Price Target
$5.03Price Target Upside169.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$38.17M
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline MomentumLexicon has multiple near-term regulatory and clinical catalysts: SONATA-HCM enrollment expected mid-2026 with topline in Q1 2027 and Zynquista NDA resubmission targeted mid-2026. These late-stage events can materially de-risk programs, enable approvals, and create durable commercial optionality or partnership value if successful.
Strengthened Liquidity And CapitalizationCash increased materially to ~$199.7M while debt declined modestly, improving runway versus prior periods. The stronger cash position and lower leverage provide durable financial flexibility to fund ongoing trials, meet near-term milestones, and reduce immediate financing pressure, supporting execution through 2026 development and regulatory milestones.
Partner Validation And Milestone EconomicsSignificant milestone payments from Novo Nordisk and program advancement under partner arrangements validate Lexicon's discovery pipeline and provide non-dilutive capital. Partner-driven funding and commercialization (e.g., Viatris filings) offer durable benefits: lower funding burden, external expertise, and potential royalty/profit streams if approvals and launches follow.
Bears Say
Negative Cash Flow ProfileLexicon remains cash-flow negative on a TTM basis (operating and free cash flow about -$39M), meaning operations do not yet self-fund. Persisting cash burn creates durable financing risk: absent recurring revenues or repeat milestones, the company may need additional debt, partnerships, or equity, which can constrain strategic choices and dilute shareholders.
Lumpy, Milestone-dependent RevenueRecent revenue growth was largely one-time and milestone-driven, with modest product net sales. This lumpy revenue profile undermines predictability and long-term self-sufficiency: sustained operating income depends on future milestone timing, approvals, or building organic sales, which are uncertain and can delay the transition to stable, recurring revenue streams.
Conditional Financing And Covenant ExposureThe $100M Hercules facility provides runway but is staged and contingent on clinical/regulatory milestones and lender consent, with tightened covenants after draws and first‑lien security/warrants. If milestones slip, access to additional tranches and covenant relief is uncertain, posing a durable liquidity and strategic-risk constraint for execution.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.72 and its highest was $2.53 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $892.83M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 38 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on May 07, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.034 by $0.034.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.05.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 444,196,380 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of $0 in its last earnings report, beating expectations of -$0.034. Following the earnings report the stock price went up 5%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.03 (169.16% Upside)
$5.03 (169.16% Upside)
Blogger Sentiment
Neutral
LXRX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 41.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.79%
12-Months-Change
Fundamentals
Return on Equity
-18.64%
Trailing 12-Months
Asset Growth
-9.69%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LXRX Company Deck
LXRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress across multiple fronts: large milestone-driven revenue, meaningful improvements in net loss, a stronger liquidity position, and clear clinical development milestones (SONATA enrollment completion mid-2026; Zynquista NDA resubmission midyear; LX9851 in Phase I; pilavapadin Phase III readiness). At the same time, several risks remain: the revenue uplift was largely one-time milestone-driven with limited organic sales, continued dependence on partners and conditional debt tranches, regulatory and enrollment uncertainties, and competitive dynamics in HCM. On balance, the highlights — particularly financial strengthening and late-stage program momentum — outweigh the lowlights, though execution risk into the second half of 2026 remains important.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$5.03
▲(169.16% Upside)
Technical Analysis
Ownership Overview
61.20% Insiders
7.54% Mutual Funds
0.73% Other Institutional Investors
27.94% Public Companies and
Individual Investors